This year LKF Central Laboratory, which specialises in international clinical trials, celebrates its 30th anniversary. Although size and services have developed significantly since the beginning, LKF´s corporate philosophy is still the same. With its dedicated team, LKF supports clinical trials with an individual and study-oriented, flexible approach with consistent high-quality laboratory standards.
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Which connection method do most industry professionals prefer: tube welding or aseptic connectors? A recent survey revealed their preferences are almost equally split between the two. But that doesn’t mean one method might not be better for your needs.
On 13 April 2021, Evotec SE launched beLAB2122 in collaboration with Bristol-Myers Squibb company and five top-tier academic institutions. Mediated and supported by BioRN Life Science Cluster Rhine-Neckar, this $20 million BRIDGE brings together leading academic institutions in Southwestern Germany with the goal of efficiently advancing novel drug discovery projects.
The pandemic showed us that we need to establish safety and effectiveness across different populations for a universally effective vaccine, including China. And, following Covid-19 development, we noted an instant increase in clinical trials conducted in China. So, why exactly is China an attractive market to consider for drug development strategies?
Just a few years ago, single-cell analyses were complex and not user-friendly. Now, thanks to professionalised workflows, the technology is finding its way into the industry. European Biotechnology spoke with Dr Michael Schnall-Levin, SVP R&D, Founding Scientist, from market leader 10X Genomics about the increasing importance of capturing cell heterogeneity for biomedical research.
Cellex Group is an experienced facility worldwide for all kind of allogeneic and autologous stem cell collections and is, besides that, growing to become a complete service provider for cellular immunotherapy products. One essential area of the portfolio is Cell Community, the perfect solution for researchers in need of cell products.
Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced: ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program can remarkably improve this situation. Coriolis, an expert for biopharmaceutical research and (formulation) development, expands its ATMP development facilities to meet the increasing market demand.
Richter-Helm, a leading steadily growing Germany-based contract development and manufacturing organization (CDMO), offers excellent services in the continuously growing market of pharmaceutical biotechnology. Two additional bioreactors with capacities of 300 litres and 1,500 litres for microbial production will be added. This includes also the establishment of mid- and downstream processing and supporting utilities on a total area of about 10,000 m².